Evidence Grade D — Primarily preclinical. 10 published studies, mostly animal models. 10 registered clinical trials.
Medically reviewed by a licensed medical professional
Ecnoglutide is a once-weekly GLP-1 treatment developed by Sciwind Biosciences in China, with a unique pharmacological feature: an extreme signalling bias that keeps the GLP-1 receptor available at the cell surface for longer, theoretically sustaining the drug's effect. Phase III trials have shown competitive weight loss results, and a partnership with Pfizer for commercialisation provides significant commercial validation.
Ecnoglutide is also known by these brand and alternate names:
10 published studies: 7 human, 0 animal, 1 in-vitro, 3 reviews
Ecnoglutide is in Phase III development (not yet approved). The SLIMMER Phase III trial (664 patients, 48 weeks) showed 15.4% weight loss at the 2.4 mg dose. A separate Phase III diabetes trial showed HbA1c reduction of 2.43%.
Ecnoglutide's biased agonism profile is its key differentiator within the competitive GLP-1 agonist landscape. Whether the extreme signalling bias translates to meaningful clinical advantages in tolerability or sustained efficacy compared to existing GLP-1 agonists will be determined by ongoing comparative data.
Ecnoglutide activates the GLP-1 receptor with exceptional selectivity for the cAMP signalling pathway while minimally triggering receptor internalisation (the process that normally reduces receptor availability after drug exposure). This biased agonism theoretically maintains receptor sensitivity over time, potentially sustaining drug effect and reducing the dose escalation needed with conventional GLP-1 agonists.
Phase III results (SLIMMER trial, 664 patients) showed 15.4% weight loss at 48 weeks, competitive with semaglutide. The extreme signalling bias (over 500,000-fold preference for one pathway over another) is genuinely novel among GLP-1 drugs. A partnership with Pfizer for Chinese commercialisation provides significant validation. All Phase III data are from Chinese populations only, and no trials outside China are planned. An oral formulation remains at Phase I with limited data. The 15.4% weight loss is competitive but not class-leading in a landscape where newer multi-target drugs are achieving over 20%. Whether the biased signalling translates to meaningful tolerability or durability advantages over conventional GLP-1 drugs remains to be demonstrated.
PeptideTrace tracks 10 registered clinical trials for Ecnoglutide sourced from ClinicalTrials.gov.
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Ecnoglutide (XW003) is a long-acting GLP-1(7-37) peptide analog with a Val8 substitution promoting cAMP-biased signaling and C18 diacid fatty acid conjugation at Lys30 for albumin binding. CAS number: 2459531-73-6. Developed by Sciwind Biosciences (Hangzhou, China). The compound uses exclusively natural amino acids, simplifying recombinant manufacturing. Half-life at steady state: 124-138 hours. Ecnoglutide received NMPA approval in China for type 2 diabetes on January 30, 2026, making it the world's first approved cAMP-biased GLP-1 agonist. An obesity NDA is under NMPA review, and Sciwind partnered with Pfizer China in February 2026 for exclusive commercialization rights.
Ecnoglutide demonstrates exceptional signaling bias: cAMP EC50 of 0.018 nM versus receptor internalization EC50 greater than 10 micromolar, representing a greater than 500,000-fold bias toward cAMP signaling over beta-arrestin recruitment. This biased agonism theoretically attenuates receptor desensitization and sustains GLP-1R signaling duration. The Val8 substitution is the key molecular modification responsible for this signaling profile, reducing beta-arrestin-mediated receptor internalization while preserving full Gs-coupled cAMP activation.
SLIMMER Phase 3 (NCT05813795; N=664; Lancet Diabetes and Endocrinology June 2025): the 2.4 mg dose achieved -15.4% weight loss at 48 weeks (placebo-adjusted -15.1%; P<0.0001), with 92.8% achieving at least 5% loss and 79.6% achieving at least 10%. EECOH-1 Phase 3 T2D (NCT05680155; N=211): HbA1c reduction of -2.43% (1.2 mg) versus -0.55% placebo, with 76.1% achieving HbA1c at or below 6.5%. Phase 2b versus liraglutide (N=206): 2.4 mg achieved -14.7% weight loss versus -8.8% for liraglutide (P<0.001). Treatment completion rates were excellent at 92% in SLIMMER.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Danuglipron's original twice-daily formulation achieved 8–13% weight loss in Phase IIb but with treatment discontinuation rates exceeding 50%, with nausea affecting up to 73% of patients. Pfizer discontinued the twice-daily formulation and is developing a once-daily modified-release version. Danuglipron is not a peptide. Its development trajectory illustrates that even effective weight loss compounds can fail commercially if tolerability is inadequate. The reformulation effort aims to reduce peak drug concentrations that likely drive the gastrointestinal side effects.
Setmelanotide is marketed as Imcivree (Rhythm Pharmaceuticals; approved November 2020 for POMC, PCSK1, or LEPR deficiency; June 2022 for Bardet-Biedl syndrome; December 2024 expanded to patients aged 2 years and older). Genetic testing confirming an eligible mutation is required before treatment. In patients with POMC or PCSK1 deficiency, approximately 80% achieved at least 10% weight loss in clinical trials. In Bardet-Biedl syndrome, 32.3% achieved the same threshold. The most common side effects are injection-site reactions and skin darkening (due to the melanocortin pathway's connection to pigmentation). Setmelanotide exemplifies precision medicine — it is highly effective in the specific genetic populations it targets but is not indicated for common obesity.
CT-388 is in Phase II/III development (not yet approved). Phase II results (469 patients, 48 weeks) showed 22.5% placebo-adjusted weight loss at the highest dose, with low discontinuation rates due to adverse events (5.9%). Phase III trials are underway. The combination of high efficacy and low discontinuation rates in Phase II is notable — many obesity drugs achieve high weight loss but suffer from tolerability-driven dropouts. Roche's $2.7 billion acquisition of the developer signals significant confidence in the programme.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
